Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2008 1
2009 1
2010 2
2011 2
2012 4
2013 1
2014 1
2015 2
2016 1
2017 1
2018 2
2019 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Recent progress in allergen immunotherapy.
Nouri-Aria KT. Nouri-Aria KT. Iran J Immunol. 2008 Mar;5(1):1-24. Iran J Immunol. 2008. PMID: 18319521 Free article. Review.
Alternative strategies include the use of adjuvants, such as nucleotide immunostimulatory sequences derived from bacteria CpG or monophosphoryl lipid A that potentiate Th1 responses. Blocking the effects of IgE using anti-IgE such as omalizumab, a recombinant humani …
Alternative strategies include the use of adjuvants, such as nucleotide immunostimulatory sequences derived from bacteria CpG or monophospho …
Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria.
Parisi GF, Papale M, Tardino LG, Manti S, Cuppari C, Salpietro C, Leonardi S. Parisi GF, et al. J Dermatolog Treat. 2018;29(sup4):10-11. doi: 10.1080/09546634.2018.1551609. J Dermatolog Treat. 2018. PMID: 30462557
Background: Omalizumab is a recombinant humanized IgG monoclonal antibody, which binds the Fc region of free IgE prevent its binding to its high-affinity receptor (FcepsilonR1) on mast cells and basophils. ...Patient and results: This article reports effective and s …
Background: Omalizumab is a recombinant humanized IgG monoclonal antibody, which binds the Fc region of free IgE prevent its b …
Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.
Lan J, Zhang Y, Song M, Cai S, Luo H, OuYang R, Yang P, Shi X, Long Y, Chen Y. Lan J, et al. Front Med (Lausanne). 2022 May 4;9:835257. doi: 10.3389/fmed.2022.835257. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35602476 Free PMC article.
Currently, there is no complete cure or targeted treatment for HIES. Omalizumab is a humanized recombinant monoclonal antibody against IgE, reducing the level of free IgE, inhibiting the binding of IgE to receptors on the surface of effector cells, and reducing the …
Currently, there is no complete cure or targeted treatment for HIES. Omalizumab is a humanized recombinant monoclonal antibody …
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.
Martin PL, Bugelski PJ. Martin PL, et al. Br J Pharmacol. 2012 Jun;166(3):806-22. doi: 10.1111/j.1476-5381.2011.01812.x. Br J Pharmacol. 2012. PMID: 22168335 Free PMC article. Review.
Data on the following approved biopharmaceuticals were included: adalimumab, anakinra, bevacizumab, canakinumab, certolizumab pegol, denosumab, eculizumab, etanercept, golimumab, infliximab, omalizumab, ranibizumab, rilonacept and ustekinumab. Some related biopharmaceutica …
Data on the following approved biopharmaceuticals were included: adalimumab, anakinra, bevacizumab, canakinumab, certolizumab pegol, denosum …
Evaluation of IgE Antibodies to Omalizumab (Xolair) and Their Potential Correlation to Anaphylaxis.
Baker DL, Nakamura GR, Lowman HB, Fischer SK. Baker DL, et al. AAPS J. 2016 Jan;18(1):115-23. doi: 10.1208/s12248-015-9821-x. Epub 2015 Sep 4. AAPS J. 2016. PMID: 26340860 Free PMC article.
Omalizumab (Xolair) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Omalizumab is used to treat IgE-mediated diseases such as chronic idiopathic urticaria (CIU) and moderate to severe allergic asthma. ...
Omalizumab (Xolair) is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). …
Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
Davies AM, Allan EG, Keeble AH, Delgado J, Cossins BP, Mitropoulou AN, Pang MOY, Ceska T, Beavil AJ, Craggs G, Westwood M, Henry AJ, McDonnell JM, Sutton BJ. Davies AM, et al. J Biol Chem. 2017 Jun 16;292(24):9975-9987. doi: 10.1074/jbc.M117.776476. Epub 2017 Apr 24. J Biol Chem. 2017. PMID: 28438838 Free PMC article.
We solved the crystal structure of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain. ...CD23 binding is inhibited sterically due to overlapping binding sites on each C3 domain. Studies of omalizumab Fab binding in soluti …
We solved the crystal structure of the complex between an omalizumab-derived Fab and IgE-Fc, with one Fab bound to each C3 domain. .. …
Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.
Metz M, Torene R, Kaiser S, Beste MT, Staubach P, Bauer A, Brehler R, Gericke J, Letzkus M, Hartmann N, Erpenbeck VJ, Maurer M. Metz M, et al. Allergy. 2019 Jan;74(1):141-151. doi: 10.1111/all.13547. Epub 2018 Oct 15. Allergy. 2019. PMID: 29974963 Clinical Trial.
BACKGROUND: Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, proved to be effective in patients with chronic spontaneous urticaria (CSU), including severe and treatment-refractory CSU. Here, we report omalizumab's effect on gene expres …
BACKGROUND: Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, proved to be effective in patients with chronic …
DARPins against a functional IgE epitope.
Baumann MJ, Eggel A, Amstutz P, Stadler BM, Vogel M. Baumann MJ, et al. Immunol Lett. 2010 Oct 30;133(2):78-84. doi: 10.1016/j.imlet.2010.07.005. Epub 2010 Jul 29. Immunol Lett. 2010. PMID: 20673836
The monoclonal anti-IgE antibody omalizumab (Xolair is mostly used for the treatment of severe allergic asthma. ...Furthermore, anti-IgE DARPins were shown to inhibit proinflammatory mediator release from rat basophilic leukemia cells expressing human high-affinity IgE rec …
The monoclonal anti-IgE antibody omalizumab (Xolair is mostly used for the treatment of severe allergic asthma. ...Furthermore, anti- …
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Milgrom H, et al. Pediatrics. 2001 Aug;108(2):E36. doi: 10.1542/peds.108.2.e36. Pediatrics. 2001. PMID: 11483846 Clinical Trial.
IgE-mediated mast cell activation contributes to chronic tissue eosinophilia and airway remodeling, with permanent loss in pulmonary function. Omalizumab (rhuMAb-E25) is a recombinant, humanized, monoclonal anti-IgE antibody of mouse origin developed for the treatme …
IgE-mediated mast cell activation contributes to chronic tissue eosinophilia and airway remodeling, with permanent loss in pulmonary functio …
Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor.
Kim B, Eggel A, Tarchevskaya SS, Vogel M, Prinz H, Jardetzky TS. Kim B, et al. Nature. 2012 Nov 22;491(7425):613-7. doi: 10.1038/nature11546. Epub 2012 Oct 28. Nature. 2012. PMID: 23103871 Free PMC article.
Inhibitors of IgE-FcepsilonRI binding have been identified and an anti-IgE therapeutic antibody (omalizumab) is used to treat severe allergic asthma. However, preformed IgE-FcepsilonRI complexes that prime cells before allergen exposure dissociate extremely slowly and cann …
Inhibitors of IgE-FcepsilonRI binding have been identified and an anti-IgE therapeutic antibody (omalizumab) is used to treat severe …
19 results